Amlodipine: a pharmacoeconomic review

References

• de Portu S, Menditto E, Scalone L et al. The pharmacoeconomic impact of amlodipine use on coronary artery disease. Pharmacological Research. 2006;54:158-63.
   PubMedGoogle Scholar
• Heart Disease and Stroke Statistics – 2004 Update, American Heart Association available at URL: http://www.americanheart.org.
   Google Scholar
• British Heart Foundation. European Cardiovascular Disease Statistics, 2000 Edition.
   Google Scholar
• Giampaoli S, Palmieri L, Capocaccia R et al. Estimating population-based incidence and prevalence of major coronary events. International Journal of Epidemiology. 2001;30:S5-S10.
   Google Scholar
• Cooper ES. Prevention: the key to progress. Circulation. 1993;87:1430-4.
   PubMedGoogle Scholar
• Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-15. Erratum in: Lancet. 2002;359:360.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. Journal of Hypertension. 2003;21(6):1055-76.
   PubMedGoogle Scholar
• Nissen SE, Tuzcu EM, Libby P et al. CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary heart disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. Journal of the American Medical Association. 2004;292:2217-26.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Staessen JA. Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies. Hypertension. 2006;48:359-61 (Erratum in: Hypertension. 2006;48:e24).
   PubMedGoogle Scholar
• Wang JG, Yan Li, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: a quantitative overview. Hypertension. 2007;50:181-8.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine. 2001;345:851-60.
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al; VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomised trial. Lancet. 2004;363:2022-31.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertension Research. 2005;28:385-407.
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;355:1955-64.
   PubMed Web of Science ®Google Scholar
• Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-35.
   PubMed Web of Science ®Google Scholar
• Greer IA, Walker JJ, McLaren M et al. Inhibition of whole blood aggregation by nicardipine, and synergism with prostacyclin in-vitro. Thrombosis Research. 1986;41:509-18.
   PubMedGoogle Scholar
• Han P, Boatwright C, Ardli NG. Effect of the calcium-entry blocking agent nifedipine on activation of human platelets and comparison with verapamil. Thrombosis and Haemostasis. 1983;50:513-17.
   PubMed Web of Science ®Google Scholar
• Rossetti F, de Portu S, Menditto E et al. Pharmacoeconomic consequences of amlodipine besylate therapy in patients undergoing PTCA. Pharmacological Research. 2006;53:197-201.
   PubMedGoogle Scholar
• Jackson CL, Bush RC, Bowyer DE. Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis. 1989;80(1):17-26.
   PubMedGoogle Scholar
• Hillegass WB, Ohman EM, Leimberger JD, Califf RM. A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. American Journal of Cardiology. 1994;73(12):835-9.
   PubMedGoogle Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of the American Medical Association. 2002;288:2981-97.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR et al; ASCOT Investigators. Prevention of cardiovascular events with an amlodipine/perindopril strategy compared with an atenolol/thiazide strategy. The Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
   PubMed Web of Science ®Google Scholar
• Pitt B, Byington RP, Furberg CD et al; PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-10.
   PubMed Web of Science ®Google Scholar
• Ogihara T, Nakao K, Fukui T et al; for the Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008;51(2):393-8.
   PubMedGoogle Scholar
• Jorgensen B, Simonsen S, Endresen K et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary Angioplasty Amlodipine REStenosis Study (CAPARES). Journal of the American College of Cardiology. 2000;35(3):592-9.
   PubMedGoogle Scholar
• Lindgren P, Buxton M, Kahan T et al; on behalf of the ASCOT trial investigators. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. Heart. 2008;94:e4
   PubMedGoogle Scholar
• Cathomas G, Erne P, Schwenkglenks M, Szucs TD. The economic efficiency of amlodipine in the treatment of coronary atherosclerosis – an analysis based on the PREVENT study. Cardiovascular Drugs and Therapy. 2002;16:61-6.
   PubMedGoogle Scholar
• Casciano R, Doyle JJ, Chen J et al. Economic benefits of amlodipine treatment in patients with coronary artery disease. Pharmacoeconomics. 2002;20(8):553-63.
   PubMedGoogle Scholar
• Casciano R, Doyle JJ, McGuire A et al. The cost-effectiveness of amlodipine treatment in patients with coronary artery disease. British Journal of Cardiology. 2002;9(2):109-14.
   Google Scholar
• Doyle JJ, McGuire A, Arocho R et al. A cost-effectiveness evaluation of amlodipine usage in patients with coronary artery disease in Sweden. International Journal of Clinical Practice. 2002;56(2):76-81.
   PubMedGoogle Scholar
• Palmer AJ, Annemans L, Roze S et al. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. Journal of Human Hypertension. 2004;18:733-8.
   PubMed Web of Science ®Google Scholar
• Rodby RA, Chiou CF, Borenstein J et al; for the Collaborative Study Group. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clinical Therapeutics. 2003;25:2102-19.
   PubMed Web of Science ®Google Scholar
• Coyle D, Rodby RA. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. Canadian Journal of Cardiology. 2004;20(1):71-9.
   PubMedGoogle Scholar
• Thaulow E, Jorgensen B, Doyle JJ et al. A pharmacoeconomic evaluation of results from the coronary angioplasty amlodipine restenosis study (CAPARES) in Norway and Canada. International Journal of Cardiology. 2002;84:23-30.
   PubMedGoogle Scholar
• Doyle JJ, Thaulow E, Jorgensen B et al. Amlodipine treatment in patients undergoing PTCA in the UK: a cost-effectiveness analysis. British Journal of Cardiology. 2002;9(1):31-6.
   Google Scholar
• Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertension Research. 2005;28:385-407.
   PubMed Web of Science ®Google Scholar
• Wang JG, Staessen JA, Li Y et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized trial. Stroke. 2006;37:1933-40.
   PubMed Web of Science ®Google Scholar
• Brown A, Garber A. Cost effectiveness of coronary heart disease prevention strategies in adults. Pharmacoeconomics. 1998;14(1):27-48.
   PubMedGoogle Scholar